Company Name, Ticker, Customers, else..

Artiva Biotherapeutics Inc (NASDAQ: ARTV)

Sector • Healthcare Industry • Biotechnology & Pharmaceuticals

Industry • Biotechnology & Pharmaceuticals

Sector • Healthcare

Artiva Biotherapeutics Inc 's

Name: Artiva Biotherapeutics Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ARTV Sales vs. its Competitors Q2 2026

Comparing the current results to its competitors, Artiva Biotherapeutics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 81.64 %, recorded in the same quarter.

• List of ARTV Competitors

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Artiva Biotherapeutics Inc , faster than the decline experienced by the competitors recorded a net loss, as well as most of its competitors.

<< ARTV Stock Performance Comparisons

<< See the full list of ARTV competitors

*Market share is calculated based on total revenue.

News about Artiva Biotherapeutics Inc Contracts

Promising Advances in B-cell Non-Hodgkin Lymphoma Treatment Insights from Artiva Biotherapeutics’ ASGCT Presentatio...

April 28, 2025
Artiva Biotherapeutics, Inc. is poised to make a significant impact in the fight against B-cell non-Hodgkin lymphoma (NHL) through its innovative therapy, AlloNK, combined with the monoclonal antibody rituximab. At the upcoming 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), Artiva plans to present longer-term Phase 1/2 data reaffirming the efficacy and safety profile of AlloNK. The preliminary findings suggest that this combination therapy not only achieves a prolonged duration of response but also results in deep B-cell depletion. Importantly, these outcomes are characterized by a well-tolerated safety profile, indicating its potential viability for community-based treatment o...

ARTV's Stock Performance relative to its Competitors

Publicly Traded Peers of Artiva Biotherapeutics Inc

Immunitybio inc
Share Performance

+14.13%

Over The Past 5 Days

Immunitybio inc

Profile

Immunitybio Inc operates on a business model that focuses on developing and commercializing innovative immunotherapies and vaccines to address various diseases and medical conditions. They aim to use their broad scientific expertise, technology platforms, and strategic partnerships to advance their products and improve patient outcomes in healthcare.

More about Immunitybio inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 9,755.150 mill.	$ 165.792 mill.	$ -992.419 mill.

Senti Biosciences Holdings Inc
Share Performance

-66.14%

This Quarter

Senti Biosciences Holdings Inc

Profile

Senti Biosciences Inc is a biotechnology company that develops and commercializes novel therapeutics using synthetic biology and gene editing technology.

More about Senti Biosciences Holdings Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 9.829 mill.	$ 0.055 mill.	$ -49.564 mill.

Sources: Artiva Biotherapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Tuesday, September 8, 2026 10:23 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Artiva Biotherapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.